Canaccord raised the firm’s price target on Boston Scientific to $81 from $77 and keeps a Buy rating on the shares. The firm believes they can look past the TAVR hiccup for now and adjust their target due to increased 2025 EPS estimates and comp group multiple expansion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific Announces Key Executive Appointments
- Boston Scientific (NYSE:BSX) Surges on Stellar Q4 Results
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific sees FY24 adjusted EPS $2.23-$2.27, consensus $2.24
- Boston Scientific sees Q1 EPS 50c-52c, consensus 52c
